Anti-TNFSF14/LIGHT/CD258 Antibody (SAR252067)
Catalog No.
F1028
Anti-TNFSF14/LIGHT/CD258 Antibody (SAR252067)
Featured Products
Quisovalimab (AVTX-002; AEVI 002; SAR 252067) is a humanized monoclonal antibody against LIGHT, a tumor necrosis factor (TNF)-related cytokine (TNFSF14) that plays an important role in COVID-19 acute respiratory distress syndrome (ARDS) and cytokine release syndrome (CRS). Quisovalimab can be used in studies such as COVID-19 acute respiratory distress syndrome.
Quality Control & DataSheet
- View current batch:
-
Purity > 90% by SDS-PAGE and SEC-HPLC analyses.
- MSDS (Material Safety Data Sheet)
- Datasheet
145 kDa
Dry ice
2427667-03-4
-80°C
2 years
Liquid
See label
For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
CHO
AVTX-002, CERC-002, AEVI-002
100 mM Pro 20 mM Arg pH 5.0. No preservative!
Q92956
Human
Unconjugated
Monoclonal
Protein A
IgG1
ELISA, FACS, Kinetics, Functional assay, Animal Model
TNFSF14 / LIGHT / CD258
Please avoid freeze-thaw cycles.